Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business - Becton Dickinson ( NYSE:BDX )
Becton Dickinson plans to separate its Biosciences and Diagnostic Solutions unit, aiming for completion by fiscal 2026. BD reported Q1 2025 sales of $5.17B, up 9.8% YoY, beating estimates. Adjusted EPS of $3.43 topped the $2.98 consensus.
https://www.benzinga.com/25/02/43532512/becton-dickinson-outlines-intent-to-separate-biosciences-and-diagnostic-solutions-business-to-enhance-focus-drive